Related Experiment Videos
Phagocytosis and bactericidal action of mouse peritoneal macrophages treated with leukotriene B4
T Demitsu1, H Katayama, T Saito-Taki
1Department of Dermatology, Jichi Medical School, Tochigi-ken, Japan.
Abstract:
The effects of exogenous leukotriene B4 (LTB4) on the resistance of mouse peritoneal macrophages against Salmonella (S.) typhimurium and Pseudomonas (P.) aeruginosa infections were studied. In vitro, LTB4 added to macrophage monolayers at final concentrations of 10(-12)-10(-8) M, enhanced their phagocytosis of S. typhimurium to 2.3 times the control level and that of P. aeruginosa to 1.8 times the control level. The intracellular killing rates were also elevated by the addition of LTB4: for S. typhimurium, 83.3% (LTB4) vs 59.1% (control) and for P. aeruginosa, 46.5% (LTB4) vs 9.2% (control). In vivo, intraperitoneally injected LTB4 (5 ng) enhanced the clearance at 24 h of intraperitoneally injected S. typhimurium from the mouse peritoneal cavity (2.38 x 10(3) +/- 0.94 x 10(3) cells [LTB4] vs 5.73 x 10(5) +/- 1.90 x 10(5) [control]) and spleen (5.00 x 10(2) +/- 0.94 x 10(2) [LTB4] vs 2.47 x 10(4) +/- 0.84 x 10(4) [control]), but this effect disappeared by 48 h. In contrast, in beige mice, an experimental model of the Chédiak-Higashi syndrome that is characterized by susceptibility to bacterial infection, there was no induction of the eliminating effect by intraperitoneal injection of LTB4. Activation of macrophages by exogenous LTB4 seemed to have contributed to such an augmented resistance of macrophages to bacterial infection. This study suggested a possible use of LTB4 in bacterial infectious diseases whereby phagocytes are able to play a key role in host defense.
Insights
Exogenous leukotriene B4 (LTB4) enhances macrophage ability to fight Salmonella and Pseudomonas infections. This suggests LTB4 could be a potential treatment for bacterial diseases involving phagocyte defense.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Macrophages are key immune cells in host defense against bacterial pathogens.
- Leukotriene B4 (LTB4) is a lipid mediator with known immunomodulatory functions.
- Understanding LTB4's role in macrophage-mediated immunity is crucial for developing new anti-bacterial strategies.
Purpose of the Study:
- To investigate the effects of exogenous leukotriene B4 (LTB4) on macrophage resistance to Salmonella typhimurium and Pseudomonas aeruginosa infections.
- To evaluate both in vitro and in vivo efficacy of LTB4 in enhancing macrophage anti-bacterial activity.
- To explore the potential therapeutic application of LTB4 in bacterial infectious diseases.
Main Methods:
- In vitro studies using mouse peritoneal macrophages exposed to LTB4 and challenged with S. typhimurium and P. aeruginosa.
- Measurement of phagocytosis enhancement and intracellular killing rates.
- In vivo experiments involving intraperitoneal injection of LTB4 in mice and assessment of bacterial clearance.
- Studies in beige mice (Chédiak-Higashi syndrome model) to assess LTB4 response.
Main Results:
- Exogenous LTB4 significantly enhanced macrophage phagocytosis of both S. typhimurium (2.3x) and P. aeruginosa (1.8x) in vitro.
- LTB4 markedly increased intracellular killing rates for S. typhimurium (83.3% vs 59.1%) and P. aeruginosa (46.5% vs 9.2%).
- In vivo, LTB4 administration improved bacterial clearance from the peritoneal cavity and spleen at 24 hours, but this effect diminished by 48 hours. Beige mice did not show enhanced clearance.
Conclusions:
- Exogenous LTB4 activates macrophages, augmenting their resistance to bacterial infections.
- LTB4 demonstrates potential as an adjunct therapy for bacterial infectious diseases where phagocytes play a critical role.
- Further research into LTB4's therapeutic applications in managing bacterial infections is warranted.